Epstein-Barr virus vaccine development: A lytic and latent protein cocktail

Frontiers in Bioscience

Volumn 13, Issue 15, 2008, Pages 5916-5927

  Lockey, Timothy D ^a   Zhan, Xiaoyan ^a   Surman, Sherri ^a   Sample, Clare E ^a,b   Hurwitz, Julia L ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Cocktail; Epstein Barr virus; Human; Interferon Gamma; Latent; Lytic; Neutralization; Review; Tetrameric; Vaccine

Indexed keywords

HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; MUS; VACCINIA VIRUS;

RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL; ANIMAL MODEL; ANTIBODY PRODUCTION; CD4+ T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOLOGY; MOUSE; NEOPLASM; REVIEW; VIROLOGY; VIRUS INFECTION;

ANIMALS; ANTIBODY FORMATION; CD4-POSITIVE T-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MICE; MODELS, ANIMAL; NEOPLASMS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 52049122803     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3126     Document Type: Article

References (64)

1. A. B. Rickinson and E. Kieff, Epstein-Barr virus. In Fields Virology. (Ed. D. M. Knipe, P. M. Howley, D. E. Griffin, M. A. Martin, R. A. Lamb, B. Roizman and S. E. Straus) pp. 2575-2627, Lippincott Williams and Wilkins, Philadelphia (2001)
2. E. Kieff and A. B. Rickinson, Epstein-Barr virus and its replication. In Fields Virology. (Ed. D. M. Knipe, P. M. Howley, D. E. Griffin, M. A. Martin, R. A. Lamb, B. Roizman and S. E. Straus) pp. 2511-2573, Lippincott Williams and Wilkins, Philadelphia (2001)
3. J. Tanner, J. Weis, D. Fearon, Y. Whang and E. Kieff: Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50, 203-213 (1987)
4. M. Hummel, D. Thorley-Lawson and E. Kieff: An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200) J Virol 49, 413-417 (1984) (Pubitemid 14221313)
5. E. Landais, X. Saulquin, M. Bonneville and E. Houssaint: Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected b cells following capture of BHRF1 antigen. J Immunol 175, 7939-7946 (2005) (Pubitemid 41798354)
6. J. Andersson: An Overview of Epstein-Barr Virus: from Discovery to Future Directions for Treatment and Prevention. Herpes 7, 76-82 (2000)
7. A. B. Jain, A. Marcos, R. Pokharna, R. Shapiro, P. A. Fontes, W. Marsh, R. Mohanka and J. J. Fung: Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 80, 1692-1698 (2005) (Pubitemid 43053993)
8. A. Humar, D. Hebert, H. D. Davies, A. Humar, D. Stephens, B. O'Doherty and U. Allen: A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 81, 856-861 (2006)
9. S. D. Rencher, K. S. Slobod, F. S. Smith and J. L. Hurwitz: Activity of transplanted CD8+ versus CD4+ cytotoxic T-cells against Epstein-Barr virus immortalized B-cell tumors in SCID mice. Transplantation 58, 629-633 (1994) (Pubitemid 24289860)
10. K. S. Slobod and J. L. Hurwitz: Adoptive Immunotherapy. Pediatr Infect Dis J 18, 467-468 (1999) (Pubitemid 29247018)
11. K. S. Slobod, E. Benaim, L. Woodruff, S. Nooner, J. Houston, M. Holladay, T. D. Lockey and J. L. Hurwitz: T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients. Immunologic Res 24, 289-301 (2001) (Pubitemid 33064387)
12. S. D. Rencher, J. A. Houston, T. D. Lockey and J. L. Hurwitz: Eliminating graft-versus-host potential from T cell immunotherapeutic populations. Bone Marrow Trans 18, 415-420 (1996) (Pubitemid 26283695)
13. C. M. Rooney, C. A. Smith, C. Y. Ng, S. K. Loftin, J. W. Sixbey, Y. Gan, D.-K. Srivastava, L. C. Bowman, R. A. Krance, M. K. Brenner and H. E. Heslop: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549-1555 (1998) (Pubitemid 28406858)
14. C. A. Smith, C. Y. C. Ng, S. K. Loftin, C. Li, H. E. Heslop, M. K. Brenner and C. M. Rooney: Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymph (1996)
15. H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. B. Brenner and C. M. Rooney: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virusspecific T lymphocytes. Nat Med 2, 551-555 (1996) (Pubitemid 26150682)
16. H. E. Heslop, M. K. Brenner and C. M. Rooney: Donor T cells to treat EBV-associated lymphoma. N Eng J Med 331, 679-680 (1994) (Pubitemid 24276876)
17. D. J. Moss, S. R. Burrows, R. Khanna, I. S. Misko and T. B. Sculley: Immune surveillance against Epstein-Barr virus. Semin Immunol 4, 97-104 (1992)
18. A. J. Morgan: Epstein-Barr virus vaccines. Vaccine 10, 563-571 (1992)
19. S. Y. Gu, T. M. Huang, L. Ruan, Y. H. Miao, H. Lu, C. M. Chu, M. Motz and H. Wolf: First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 84, 171-177 (1995)
20. M. Mackett and J. R. Arrand: Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. EMBO J 4, 3229-3234 (1985)
21. L. E. Wallace, J. Wright, D. O. Ulaeto, A. J. Morgan and A. B. Rickinson: Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones. J Virol 65, 3821-3828 (1991)
22. A. J. Morgan, S. Finerty, K. Lovgren, F. T. Scullion and B. Morein: Prevention of Epstein-Barr (EB) virusinduced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. J Gen Virol 69 ( Pt 8), 2093-2096 (1988)
23. M. A. Epstein, A. J. Morgan, S. Finerty, B. J. Randle and J. K. Kirkwood: Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 318, 287-289 (1985) (Pubitemid 16206730)
24. A. J. Morgan, M. Mackett, S. Finerty, J. R. Arrand, F. T. Scullion and M. A. Epstein: Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J Med Virol 25, 189-195 (1988)
25. S. Gu, T. Huang, Y. Miao, L. Ruan, Y. Zhao, C. Han, Y. Xiao, J. Zhu and H. Wolf: A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. Chin Med Sci J 6, 241-243 (1991)
26. M. Moutschen, P. Leonard, E. M. Sokal, F. Smets, M. Haumont, P. Mazzu, A. Bollen, F. Denamur, P. Peeters, G. Dubin and M. Denis: Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25, 4697-4705 (2007) (Pubitemid 46766584)
27. S. A. Thomson, R. Khanna, J. Gardner, S. R. Burrows, B. Coupar, D. J. Moss and A. Suhrbier: Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci U S A 92, 5845-5849 (1995)
28. J. Duraiswamy, M. Sherritt, S. Thomson, J. Tellam, L. Cooper, G. Connolly, M. Bharadwaj and R. Khanna: Therapeutic LMP1 polyepitope vaccine for EBVassociated Hodgkin disease and nasopharyngeal carcinoma. Blood 101, 3150-3156 (2003) (Pubitemid 36858009)
29. R. Khanna, S. R. Burrows, A. Neisig, J. Neefjes, D. J. Moss and S. L. Silins: Hierarchy of Epstein-Barr virusspecific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: implications for epitope-based antiviral vaccines. J Virol 71, 7429-7435 (1997) (Pubitemid 27391682)
30. E. Landais, X. Saulquin, E. Scotet, L. Trautmann, M. A. Peyrat, J. L. Yates, W. W. Kwok, M. Bonneville and E. Houssaint: Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 103, 1408-1416 (2004) (Pubitemid 38168656)
31. S. A. Thomson, S. R. Burrows, I. S. Misko, D. J. Moss, B. E. Coupar and R. Khanna: Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design. J Virol 72, 2246-2252 (1998) (Pubitemid 28100782)
32. G. S. Taylor, T. A. Haigh, N. H. Gudgeon, R. J. Phelps, S. P. Lee, N. M. Steven and A. B. Rickinson: Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+-and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol 78, 768-778 (2004) (Pubitemid 38067599)
33. R. Khanna, M. Sherritt and S. R. Burrows: EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol 162, 3063-3069 (1999) (Pubitemid 29309337)
34. R. Khanna, D. J. Moss and S. R. Burrows: Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 170, 49-64 (1999) (Pubitemid 29490744)
35. V. Turcanova and P. Hollsberg: Sustained CD8+ T-cell immune response to a novel immunodominant HLAB* 0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein. J Med Virol 72, 635-645 (2004) (Pubitemid 38296076)
36. S. Jung, Y. K. Chung, S. H. Chang, J. Kim, H. R. Kim, H. S. Jang, J. C. Lee, G. H. Chung and Y. S. Jang: DNAmediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen. Mol Cells 12, 41-49 (2001) (Pubitemid 33617162)
37. M. Y. Lee, Y. Zhou, R. W. Lung, M. L. Chye, W. K. Yip, S. Y. Zee and E. Lam: Expression of viral capsid protein antigen against Epstein-Barr virus in plastids of Nicotiana tabacum cv. SR1. Biotechnol Bioeng (2006)
38. K. Bickham and C. Munz: Contrasting roles of dendritic cells and B cells in the immune control of Epstein-Barr virus. Curr Top Microbiol Immunol 276, 55-76 (2003) (Pubitemid 36538347)
39. M. Gong, T. Ooka, T. Matsuo and E. Kieff: Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB. J Virol 61, 499-508 (1987) (Pubitemid 17001749)
40. R. J. Pither, L. Nolan, J. Tarlton, J. Walford and A. J. Morgan: Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera. J Gen Virol 73 ( Pt 6), 1409-1415 (1992)
41. R. Gavioli, M. G. Kurilla, P. O. De Campos-Lima, L. E. Wallace, R. Dolcetti, R. J. Murray, A. B. Rickinson and M. G. Masucci: Multiple HLA A11-restricted cytotoxic Tlymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol 67, 1572-1578 (1993) (Pubitemid 23067665)
42. R. Gavioli, P. O. De Campos-Lima, M. G. Kurilla, E. Kieff, G. Klein and M. G. Masucci: Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: Implications for down-regulation of HLA-A11 in Burkitt lymphoma. Proc Natl Acad Sci USA 89, 5862-5866 (1992)
43. R. J. Murray, M. G. Kurilla, H. M. Griffin, J. M. Brooks, M. Mackett, J. R. Arrand, M. Rowe, S. R. Burrows, D. J. Moss, E. Kieff and A. B. Rickinson: Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci (USA) 87, 2906-2910 (1990)
44. L. Petti, J. Sample, F. Wang and E. Kieff: A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J Virol 62, 1330-1338 (1988) (Pubitemid 18082947)
45. B. Moss, Relication of poxviruses. In Virology. (Ed. B. N. Fields) pp. 685-703, Raven Press, New York, N.Y. 1985.
46. G. L. Smith and B. Moss: Vaccinia virus expression vectors: construction, properties and applications. BioTechniques Nov/Dec, 306-312 (1984)
47. K. W. Ryan, R. J. Owens and J. L. Hurwitz, Preparation and use of vaccinia virus vectors for HIV protein expression and immunization. In Immunology methods manual. (Ed. I. Lefkovits) pp. 1995-2015, Academic Press, London, England 1997.
48. S. F. Tsang, F. Wang, K. M. Izumi and E. Kieff: Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression. J Virol 65, 6765-6771 (1991)
49. D. Marshall and C. Sample: Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J Virol 69, 3624-3630 (1995)
50. U. K. Laemmli: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685 (1970)
51. G. Miller, T. Shope, H. Lisco, D. Stitt and M. Lipman: Epstein-Barr virus: Transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci (USA) 69, 383-387 (1972)
52. R. Baer, A. T. Bankier, M. D. Biggin, P. L. Deininger, P. J. Farrell, T. J. Gibson, G. Hatfull, G. S. Hudson, S. C. Satchwell, C. Seguin, P. S. Tuffnell and B. G. Barrell: DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207-211 (1984) (Pubitemid 14090708)
53. D. J. Moss and J. H. Pope: Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol 17, 233-236 (1972)
54. J. W. Kappler, B. Skidmore, J. White and P. Marrack: Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J Exp Med 153, 1198-1214 (1981) (Pubitemid 11107588)
55. D. L. Woodland, M. P. Happ, J. Bill and E. Palmer: Requirement for cotolerogenic gene products in the clonal deletion of I-E reactive cells. Science 247, 964-967 (1990)
56. B. Neuhierl, R. Feederle, W. Hammerschmidt and H. J. Delecluse: Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci U S A 99, 15036-15041 (2002) (Pubitemid 35334605)
57. R. J. Murray, M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff and A. B. Rickinson: Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr Virus (EBV) :Implications for the immune control of EBV-positive malignancies. J Exp Med 176, 157-168 (1992)
58. K. N. Heller, C. Gurer and C. Munz: Virus-specific CD4+ T cells: ready for direct attack. J Exp Med 203, 805-808 (2006)
59. K. S. Slobod, A. S. Freiberg, J. E. Allan, S. D. Rencher and J. L. Hurwitz: T-cell receptor heterogeneity among Epstein-Barr Virus-stimulated T-cell populations. Virology 196, 179-189 (1993)
60. R. Khanna, S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff and D. J. Moss: Localization of Epstein-Barr Virus cytotoxic T cell epitopes using recombinant Vaccinia: Implications for vaccine development. J Exp Med 176, 169-176 (1992)
61. S. Nikiforow, K. Bottomly, G. Miller and C. Munz: Cytolytic CD4 (+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 77, 12088-12104 (2003) (Pubitemid 37339862)
62. K. Bickham, K. Goodman, C. Paludan, S. Nikiforow, M. L. Tsang, R. M. Steinman and C. Munz: Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro. J Exp Med 198, 1653-1663 (2003) (Pubitemid 37494158)
63. R. Omiya, C. Buteau, H. Kobayashi, C. V. Paya and E. Celis: Inhibition of EBV-induced lymphoproliferation by CD4 (+) T cells specific for an MHC class II promiscuous epitope. J Immunol 169, 2172-2179 (2002) (Pubitemid 34857685)
64. D. J. Moss, R. Khanna and M. Bharadwaj: Will a vaccine to nasopharyngeal carcinoma retain orphan status? Dev Biol (Basel) 110, 67-71 (2002)